secwatch.observer — SEC 8-K summary
======================================

Issuer:     Larimar Therapeutics, Inc. (LRMR)
CIK:        0001374690
Form:       8-K
Filed at:   2024-05-31T23:59:59+00:00
Accession:  0000950170-24-067306
Event type: other
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Larimar Therapeutics shareholders elect Class I directors, approve all proposals at 2024 annual meeting
--------------------------------------------------------------------------------

- Jonathan Leff and Jeffrey Sherman re-elected as Class I directors with ~40.7M and ~51.1M votes for, respectively.
- Advisory vote on executive compensation approved with ~48.8M for, ~2.4M against.
- Ratification of PricewaterhouseCoopers LLP as auditor for FY2024 approved with ~59.6M for.
- Amendment to certificate of incorporation regarding officer exculpation approved with ~50.9M for.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1374690/000095017024067306/0000950170-24-067306-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1374690/000095017024067306/lrmr-20240529.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-067306

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer